Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 17, Issue 1, Pages 16-21Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1056-8727(02)00183-6
Keywords
serum AGE; type 1 diabetes; diabetic nephropathy; diabetic retinopathy
Categories
Ask authors/readers for more resources
We investigated whether serum levels of N-(carboxymethyl)lysine (CML), non-CML advanced glycation endproducts (AGEs), or pentosidine are associated with severity of diabetic microvascular complications in patients with Type I diabetes. Serum levels of CML, non-CML AGE. and pentosidine were measured by an enzyme-linked immunosorbent assay in 38 males, and 47 females aged 31 8 years (mean+/-S.D.) with Type 1 diabetes for 183+/-7.0 years. There was a significant correlation between serum levels of CML or non-CML AGE and current MbA(1c) level (P<.01 and P<.05, respectively). The serum levels of non-CML AGE, but not CML or pemosidine, were significantly increased as normal renal status advanced to microalbuminuria, clinical nephropathy, and hemodialysis (P<.0001) and were positively correlated with urinary albumin excretion (UAE) in patients with Type I diabetes (P<.0001). A significant elevation of serum non-CML AGE was found in association with the severity of diabetic retinopathy (P<.05), We found in the present study that CML levels were also increased in the stage of simple retinopathy, the early stage of clinically evident retinopathy (P<.05). Serum levels of non-CML AGE were significantly associated with the severity of diabetic nephropathy and retinopathy, suggesting a role of non-CML AGE in the progression of microvascular complications in patients with Type 1 diabetes. Since serum levels of CML were significantly increased in patients with simple retinopathy, CML may participate in the initiation of diabetic retinopathy. (C) 2003 Elsevier Science Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available